Telemedicine startup Medici raises $24M Series B as demand surges due to COVID-19 pandemic, bringing Medici's total raised since 2016 to over $70M
Mary Ann Azevedo / Crunchbase News :
Context & Ripple Effects
Medici's $24M Series B lands mid-way through a pandemic-driven funding wave in virtual care. The chat-first model it competes on was already drawing venture money before COVID — CirrusMD raised a $15M Series B for its chat-based doctor access in May 2019 — but the pandemic turned that cadence into a sprint.
Within months of Medici's round, Doctor on Demand pulled in a $75M Series D led by General Atlantic, and the wave kept building through 2021: Curai's $27.5M Series B, Current Health's $43M raise after a reported 3,000% revenue jump, Zocdoc's $150M growth round following its pivot from scheduling into telehealth, and Meru Health's $38M package. Medici is one data point in a sector where every player is raising simultaneously.
First-order effects
- Medici gains fresh capital to scale its virtual-care platform exactly when patient demand is surging, extending a funding run that has topped $70M since 2016.
- The round puts Medici in direct competition for the same health-system and payer customers being courted by better-capitalized rivals like Doctor on Demand ($240M total raised).
Second-order effects
- The simultaneous raises force an arms race in sales and distribution: with Zocdoc pivoting in from scheduling and Current Health posting triple-digit-percent growth, differentiation shifts from having telehealth to proving clinical outcomes and integration.
- Health systems and insurers gain negotiating leverage as funded vendors compete on price and bundling, pressuring margins across the telemedicine vendor market.
Third-order effects
- If the pattern holds, telehealth consolidates from dozens of venture-funded point solutions into a smaller set of scaled platforms, with late-stage money (Zocdoc's $150M, Doctor on Demand's $240M cumulative) marking who survives the shakeout.
- Pandemic-era adoption converts telemedicine from an optional perk into expected infrastructure in care delivery, making reimbursement and regulatory treatment of virtual visits the next battleground rather than demand itself.
The trend: COVID-19 accelerated telemedicine from a niche service into a core care-delivery channel, with venture rounds scaling up in size and stage across the entire category through 2021.